Cannabics Pharmaceuticals Inc.

Company Name: Cannabics Pharmaceuticals

Company Website:

Contact Name: Eyal Barad

Contact Email:

Company's Bio: Cannabics Pharmaceuticals Inc. (CNBX) is a U.S. public company that has developed a platform which leerages novel drug-screening tools and artificial intelligence to develop cannabinoid-based therapies for cancer that are more precise to a patient’s genetic profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer.

C-Suite Bio's: Eyal Barad - CEO and Co-founder: Core member of Cannabics’s founding team. Prior to becoming CEO at Cannabics, Mr. Barad spent years in the online media world, taking part in many different ventures and businesses. Alongside serving as the CEO of a digital media company for over 13 years, Mr. Barad also participated in other business collaborations in many different areas including, but not limited to, the development and use of big-data and Artificial Intelligence to develop predictive models for decision-making processes. Eyal has a BA in Economics & International Relations from the Hebrew University in Jerusalem and an MBA with Honors from Haifa University.

Dr. Eyal Ballan - Co-founder & CTO: Holds a Ph.D. in Neurophysiology, Brain Waves and Cortical Connectivity in Attention. After obtaining his Ph.D. he was an entrepreneur in the field of neurofeedback and developed “Luna Mind” – recreational brain-computer interfaces. Dr. Ballan holds an M.Sc. from Tel-Aviv University – Magna Cum Laude – in molecular biology and anticancer drug development. Dr. Ballan was part of the research team which developed Salirasib (Treatment for Non-Small Cell Lung Cancer). Since 2005 Eyal has been teaching the “Second Attention”- Neuro-Physiological aspects of Higher Perception and Cognition.

Growth Plan:

Does the Company Touch the Plant?: Yes


coming soonDan Humiston